{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Controlled+and+matched+powder&page=3",
    "query": {
      "intervention": "Controlled and matched powder",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 136,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Controlled+and+matched+powder&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Controlled+and+matched+powder&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-02T12:11:47.478Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05773053",
      "title": "A Study of NT 201 Doses in the Treatment of Platysma Prominence",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Platysma Prominence"
      ],
      "interventions": [
        {
          "name": "NT 201",
          "type": "DRUG"
        },
        {
          "name": "NT 201 Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merz Aesthetics GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 73,
      "start_date": "2023-03-22",
      "completion_date": "2024-01-24",
      "has_results": false,
      "last_update_posted_date": "2024-10-21",
      "last_synced_at": "2026-10-02T12:11:47.478Z",
      "location_count": 7,
      "location_summary": "Washington D.C., District of Columbia • Aventura, Florida • Coral Gables, Florida + 3 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        },
        {
          "city": "Verona",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05773053"
    },
    {
      "nct_id": "NCT01641081",
      "title": "Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Formoterol Fumarate in the Pressair DPI, Low Dose",
          "type": "DRUG"
        },
        {
          "name": "Formoterol Fumarate in the Pressair DPI, High Dose",
          "type": "DRUG"
        },
        {
          "name": "Foradil Aerolizer, Low Dose",
          "type": "DRUG"
        },
        {
          "name": "Foradil Aerolizer, High Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 174,
      "start_date": "2012-06",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2017-02-28",
      "last_synced_at": "2026-10-02T12:11:47.478Z",
      "location_count": 29,
      "location_summary": "Phoenix, Arizona • Encinitas, California • Los Angeles, California + 26 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01641081"
    },
    {
      "nct_id": "NCT03949426",
      "title": "Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "KPG-818",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kangpu Biopharmaceuticals, Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-05-01",
      "completion_date": "2019-09-29",
      "has_results": false,
      "last_update_posted_date": "2020-02-25",
      "last_synced_at": "2026-10-02T12:11:47.478Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03949426"
    },
    {
      "nct_id": "NCT02289495",
      "title": "A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "GSK2838232",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 24,
      "start_date": "2014-11-18",
      "completion_date": "2015-06-27",
      "has_results": false,
      "last_update_posted_date": "2017-05-09",
      "last_synced_at": "2026-10-02T12:11:47.478Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02289495"
    },
    {
      "nct_id": "NCT04456998",
      "title": "GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Artery Hypertension"
      ],
      "interventions": [
        {
          "name": "GB002 (seralutinib)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Generic Dry Powder Inhaler",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 86,
      "start_date": "2020-11-12",
      "completion_date": "2022-11-01",
      "has_results": true,
      "last_update_posted_date": "2023-11-07",
      "last_synced_at": "2026-10-02T12:11:47.478Z",
      "location_count": 36,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Sacramento, California + 31 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Barbara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04456998"
    },
    {
      "nct_id": "NCT07792616",
      "title": "Electrical Neuromodulation for Modifying Spinal Network Involved in Spasticity",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Cord Injuries (Complete and Incomplete)",
        "Spinal Cord Injury",
        "Spinal Cord Injury Cervical",
        "Spinal Cord Injury Thoracic",
        "Spinal Cord Injuries",
        "Spasticity",
        "Spasm",
        "Muscle Spasticity",
        "Muscle Hypertonia",
        "Muscle Spasm"
      ],
      "interventions": [
        {
          "name": "Transcutaneous spinal stimulation at 30 Hz",
          "type": "OTHER"
        },
        {
          "name": "Transcutaneous spinal stimulation at 75 Hz",
          "type": "OTHER"
        },
        {
          "name": "Tizanidine",
          "type": "DRUG"
        },
        {
          "name": "Baclofen",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Mississippi Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2022-07-13",
      "completion_date": "2027-07-14",
      "has_results": false,
      "last_update_posted_date": "2026-08-28",
      "last_synced_at": "2026-10-02T12:11:47.478Z",
      "location_count": 2,
      "location_summary": "Jackson, Mississippi",
      "locations": [
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07792616"
    },
    {
      "nct_id": "NCT04856865",
      "title": "ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Food Allergy"
      ],
      "interventions": [
        {
          "name": "Low dose ADP101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High dose ADP101",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pooled Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alladapt Immunotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "4 Years to 55 Years"
      },
      "enrollment_count": 73,
      "start_date": "2021-04-20",
      "completion_date": "2022-12-13",
      "has_results": true,
      "last_update_posted_date": "2024-05-16",
      "last_synced_at": "2026-10-02T12:11:47.478Z",
      "location_count": 15,
      "location_summary": "Mission Viejo, California • Rolling Hills Estates, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04856865"
    },
    {
      "nct_id": "NCT07646613",
      "title": "Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "ASY202",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Placebo",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Aspeya, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 108,
      "start_date": "2026-05-19",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-02T12:11:47.478Z",
      "location_count": 6,
      "location_summary": "Walnut Creek, California • Orlando, Florida • Las Vegas, Nevada + 2 more",
      "locations": [
        {
          "city": "Walnut Creek",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07646613"
    },
    {
      "nct_id": "NCT04629170",
      "title": "Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy",
        "Enteric Hyperoxaluria"
      ],
      "interventions": [
        {
          "name": "SYNB8802",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synlogic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 77,
      "start_date": "2020-11-04",
      "completion_date": "2023-01-17",
      "has_results": false,
      "last_update_posted_date": "2024-03-08",
      "last_synced_at": "2026-10-02T12:11:47.478Z",
      "location_count": 4,
      "location_summary": "Tucson, Arizona • Tampa, Florida • Knoxville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04629170"
    },
    {
      "nct_id": "NCT01674231",
      "title": "The Effects Grapes on Health Indices",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity",
        "Inflammation",
        "Cardiovascular Disease",
        "Oxidative Stress"
      ],
      "interventions": [
        {
          "name": "Grape in the form of freeze-dried whole grape powder",
          "type": "OTHER"
        },
        {
          "name": "Grape powder placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2012-08",
      "completion_date": "2015-04",
      "has_results": false,
      "last_update_posted_date": "2017-05-30",
      "last_synced_at": "2026-10-02T12:11:47.478Z",
      "location_count": 1,
      "location_summary": "Davis, California",
      "locations": [
        {
          "city": "Davis",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01674231"
    }
  ]
}